Advocacy intelligence hub — real-time data for patient organizations
Azienda Ospedaliero Universitaria di Cagliari — PHASE4
AstraZeneca — PHASE3
Fasenra: FDA approved
treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA)
Imperial College London — PHASE2
University Medical Center Groningen
NS Pharma, Inc. — PHASE2
Guangdong Hengrui Pharmaceutical Co., Ltd — PHASE2, PHASE3
GlaxoSmithKline — PHASE3
Assistance Publique - Hôpitaux de Paris — PHASE3
NUCALA: FDA approved
NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Fasenra
AstraZeneca Pharmaceuticals LP
Fasenra
(benralizumab)Orphan drugAstraZeneca Pharmaceuticals LP
Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the h...
NUCALA
(mepolizumab)Orphan drugGlaxoSmithKline LLC
Interleukin-5 Antagonist [EPC]
12.1 Mechanism of Action Mepolizumab is an IL-5 antagonist (IgG1 kappa). IL-5 is the major cytokine responsible for the growth and differentiation, re...
Browse all Eosinophilic granulomatosis with polyangiitis news →
Peter A Merkel, MD, MPH
University of Pennsylvania
📍 Tampa, Florida
Christian Pagnoux, MD
MOUNT SINAI HOSPITAL
Michael Wechsler, MD, MD
Brigham and Women's Hospital
📍 DENVER, CO
Peter Merkel, MD, MPH, MD, MPH
University of Pennsylvania
📍 RADNOR, PA
Loic Guillevin, MD, PhD
French Vasculitis Study Group
Loic GUILLEVIN, MD, PhD
Assistance Publique - Hôpitaux de Paris
View all Eosinophilic granulomatosis with polyangiitis specialists →